All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Gérard Socié, Hôpital Saint-Louis, Paris, FR. We asked, How would you treat acute GvHD (aGvHD) in your clinic (an EU perspective)?
How would you treat aGvHD in your clinic (an EU perspective)?
Socié begins by highlighting the main differences between aGvHD treatment in the EU and in the US. Socié then discusses the use of steroids in aGvHD treatment, despite 40–50% of patients becoming steroid-resistant. Finally, Socié talks about the current standard of care in steroid-resistant aGvHD.
Considerations in the treatment of aGvHD
In a recent publication from the American Society of Hematology Education Program, Newell and Holtan discussed important factors to consider during the treatment of acute graft-versus-host disease (aGvHD),...
Prospective study investigating a mesenchymal stem cells infusion, remestemcel-L, in pediatric patients with steroid-refractory acute GvHD
A phase III study (NCT02336230) designed to further evaluate the efficacy and safety of remestemcel-L in...
Ruxolitinib treatment for patients with steroid-refractory GvHD following hematopoietic stem cell transplantation
Dr. Sameem Abedin published results from a single-centre, retrospective analysis examining outcomes and infection related events for...
Subscribe to get the best content related to GvHD delivered to your inbox